AstraZeneca to buy fusion for $2 billion

​​The deal gives AstraZeneca a foothold in the radiopharmaceutical drugs market, which has seen increasing investor interest since 2021 when data from Novartis' treatment showed that the drug extended survival for prostate cancer patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/26Rk0iU
via IFTTT

0 comments:

Post a Comment